|
1
|
Shinada M, Suzuki H, Hanyu M, Igarashi C, Matsumoto H, Takahashi M, Hihara F, Tachibana T, Sogawa C, Zhang MR, Higashi T, Sato H, Kurihara H, Yoshii Y, Doi Y. Trace Metal Impurities Effects on the Formation of [ 64Cu]Cu-diacetyl-bis( N4-methylthiosemicarbazone) ([ 64Cu]Cu-ATSM). Pharmaceuticals (Basel) 2023; 17:10. [PMID: 38275997 PMCID: PMC10821298 DOI: 10.3390/ph17010010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2023] [Revised: 12/15/2023] [Accepted: 12/19/2023] [Indexed: 01/27/2024] Open
Abstract
[64Cu]Cu-diacetyl-bis(N4-methylthiosemicarbazone) ([64Cu]Cu-ATSM) is a radioactive hypoxia-targeting therapeutic agent being investigated in clinical trials for malignant brain tumors. For the quality management of [64Cu]Cu-ATSM, understanding trace metal impurities' effects on the chelate formation of 64Cu and ATSM is important. In this study, we conducted coordination chemistry studies on metal-ATSM complexes. First, the effects of nonradioactive metal ions (Cu2+, Ni2+, Zn2+, and Fe2+) on the formation of [64Cu]Cu-ATSM were evaluated. When the amount of Cu2+ or Ni2+ added was 1.2 mol or 288 mol, equivalent to ATSM, the labeling yield of [64Cu]Cu-ATSM fell below 90%. Little effect was observed even when excess amounts of Zn2+ or Fe2+ were added to the ATSM. Second, these metals were reacted with ATSM, and chelate formation was measured using ultraviolet-visible (UV-Vis) absorption spectra. UV-Vis spectra showed a rapid formation of Cu2+ and the ATSM complex upon mixing. The rate of chelate formation by Ni2+ and ATSM was lower than that by Cu-ATSM. Zn2+ and Fe2+ showed much slower reactions with the ATSM than Ni2+. Trace amounts of Ni2+, Zn2+, and Fe2+ showed little effect on [64Cu]Cu-ATSM' quality, while the concentration of impurity Cu2+ must be controlled. These results can provide process management tools for radiopharmaceuticals.
Collapse
Affiliation(s)
- Mitsuhiro Shinada
- Faculty of Science, Toho University, Funabashi 274-8510, Japan; (M.T.); (T.T.); (Y.D.)
- Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba 263-8555, Japan; (H.S.); (M.H.); (C.I.); (H.M.); (F.H.); (C.S.); (M.-R.Z.); (T.H.)
- Kanagawa Cancer Center, Kanagawa 241-8515, Japan; (H.S.); (H.K.)
| | - Hisashi Suzuki
- Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba 263-8555, Japan; (H.S.); (M.H.); (C.I.); (H.M.); (F.H.); (C.S.); (M.-R.Z.); (T.H.)
| | - Masayuki Hanyu
- Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba 263-8555, Japan; (H.S.); (M.H.); (C.I.); (H.M.); (F.H.); (C.S.); (M.-R.Z.); (T.H.)
| | - Chika Igarashi
- Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba 263-8555, Japan; (H.S.); (M.H.); (C.I.); (H.M.); (F.H.); (C.S.); (M.-R.Z.); (T.H.)
- Kanagawa Cancer Center, Kanagawa 241-8515, Japan; (H.S.); (H.K.)
| | - Hiroki Matsumoto
- Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba 263-8555, Japan; (H.S.); (M.H.); (C.I.); (H.M.); (F.H.); (C.S.); (M.-R.Z.); (T.H.)
- Kanagawa Cancer Center, Kanagawa 241-8515, Japan; (H.S.); (H.K.)
| | - Masashi Takahashi
- Faculty of Science, Toho University, Funabashi 274-8510, Japan; (M.T.); (T.T.); (Y.D.)
- Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba 263-8555, Japan; (H.S.); (M.H.); (C.I.); (H.M.); (F.H.); (C.S.); (M.-R.Z.); (T.H.)
| | - Fukiko Hihara
- Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba 263-8555, Japan; (H.S.); (M.H.); (C.I.); (H.M.); (F.H.); (C.S.); (M.-R.Z.); (T.H.)
| | - Tomoko Tachibana
- Faculty of Science, Toho University, Funabashi 274-8510, Japan; (M.T.); (T.T.); (Y.D.)
- Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba 263-8555, Japan; (H.S.); (M.H.); (C.I.); (H.M.); (F.H.); (C.S.); (M.-R.Z.); (T.H.)
| | - Chizuru Sogawa
- Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba 263-8555, Japan; (H.S.); (M.H.); (C.I.); (H.M.); (F.H.); (C.S.); (M.-R.Z.); (T.H.)
| | - Ming-Rong Zhang
- Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba 263-8555, Japan; (H.S.); (M.H.); (C.I.); (H.M.); (F.H.); (C.S.); (M.-R.Z.); (T.H.)
| | - Tatsuya Higashi
- Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba 263-8555, Japan; (H.S.); (M.H.); (C.I.); (H.M.); (F.H.); (C.S.); (M.-R.Z.); (T.H.)
| | - Hidemitsu Sato
- Kanagawa Cancer Center, Kanagawa 241-8515, Japan; (H.S.); (H.K.)
| | - Hiroaki Kurihara
- Kanagawa Cancer Center, Kanagawa 241-8515, Japan; (H.S.); (H.K.)
| | - Yukie Yoshii
- Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba 263-8555, Japan; (H.S.); (M.H.); (C.I.); (H.M.); (F.H.); (C.S.); (M.-R.Z.); (T.H.)
- Kanagawa Cancer Center, Kanagawa 241-8515, Japan; (H.S.); (H.K.)
| | - Yoshihiro Doi
- Faculty of Science, Toho University, Funabashi 274-8510, Japan; (M.T.); (T.T.); (Y.D.)
| |
Collapse
|
|
3
|
Special radionuclide production activities – recent developments at QST and throughout Japan. RADIOCHIM ACTA 2022. [DOI: 10.1515/ract-2021-1124] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Abstract
National Institutes for Quantum Science and Technology (QST), formerly known as the National Institute of Radiological Sciences (NIRS), has been engaged in work on radiopharmaceutical science using cyclotrons since 1974. Eight pioneering researchers founded the basis of this field of research at NIRS, and to the present, many researchers and technicians have accumulated both scientific and technical achievements, as well as inherited the spirit of research. Besides, in recent years, we have developed production systems with AVF-930 cyclotron for various ‘non-standard’ radioisotopes applied in both diagnosis and therapy. Here, we review the past 50 years of our activities on radioisotope and radiopharmaceutical development, as well as more recent activities.
Collapse
|
|
4
|
Characterization and Stabilization of a New 64Cu-Labeled Anti-EGFR Antibody NCAB001 for the Early Detection of Pancreatic Cancer with Positron Emission Tomography. Pharmaceutics 2021; 14:pharmaceutics14010067. [PMID: 35056963 PMCID: PMC8779674 DOI: 10.3390/pharmaceutics14010067] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2021] [Revised: 12/24/2021] [Accepted: 12/25/2021] [Indexed: 12/20/2022] Open
Abstract
Early diagnosis of pancreatic cancer using current imaging modalities remains challenging. We have developed a new approach to identify tumor lesions ≥ 3 mm in the pancreas by positron emission tomography (PET) with a new intraperitoneally administered 64Cu-labeled anti-epidermal growth factor receptor (EGFR) antibody (encoded as NCAB001), called 64Cu-NCAB001 ipPET. Generally, in clinical research, a radiometal-antibody complex must be prepared immediately before use at the imaging site. To make 64Cu-NCAB001 ipPET available to daily clinical practices in a sustainable way, the NCAB001-chelator conjugate and 64Cu-NCAB001 must be characterized and stabilized. NCAB001 was manufactured under cGMP conditions. NCAB001 was conjugated with a bifunctional chelator (p-SCN-Bn-PCTA), and the antibody-chelator conjugate (PCTA-NCAB001) was characterized by LC/MS and ELISA. Thereafter, to effectively manufacture 64Cu-NCAB001, we developed a new formulation to stabilize PCTA-NCAB001 and 64Cu-NCAB001. An average of three PCTA chelators were conjugated per molecule of NCAB001. The relative binding potency of PCTA-NCAB001 was comparable to cetuximab. The formulation consisting of acetate buffer, glycine, and polysorbate-80 stabilized PCTA-NCAB001 for a year-long storage. Additionally, this formulation enabled the stabilization of 64Cu-NCAB001 for up to 24 h after radiolabeling with a sufficient radioactivity concentration for clinical use. These results may accelerate the future use of 64Cu-NCAB001 ipPET in clinical settings for the early diagnosis and treatment of pancreatic cancer.
Collapse
|
|
5
|
Suzuki H, Kise S, Kaizuka Y, Watanabe R, Sugawa T, Furukawa T, Fujii H, Uehara T. Copper-64-Labeled Antibody Fragments for Immuno-PET/Radioimmunotherapy with Low Renal Radioactivity Levels and Amplified Tumor-Kidney Ratios. ACS OMEGA 2021; 6:21556-21562. [PMID: 34471758 PMCID: PMC8388099 DOI: 10.1021/acsomega.1c02516] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/13/2021] [Accepted: 07/08/2021] [Indexed: 06/01/2023]
Abstract
Copper-64 (64Cu)-labeled antibody fragments such as Fab are useful for molecular imaging (immuno-PET) and radioimmunotherapy. However, these fragments cause high and persistent localization of radioactivity in the kidneys after injection. To solve this problem, this study assessed the applicability of a molecular design to 64Cu, which reduces renal radioactivity levels by liberating a urinary excretory radiometabolite from antibody fragments at the renal brush border membrane (BBM). Since 1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA) forms a stable complex with Cu, NOTA-conjugated Met-Val-Lys-maleimide (NOTA-MVK-Mal), which is a radio-gallium labeling agent for antibody fragments, was evaluated for applicability to 64Cu. The MVK linkage was recognized by the BBM enzymes to liberate [64Cu]Cu-NOTA-Met although the recognition of the MVK sequence for the [64Cu]Cu-NOTA-MVK derivative was reduced compared with that of its [67Ga]Ga-counterpart, probably due to the difference in the charge of the metal-NOTA complexes. When injected into mice, [64Cu]Cu-NOTA-MVK-Fab resulted in similar renal radioactivity levels to the 67Ga-labeled counterpart. In addition, [64Cu]Cu-NOTA-MVK-Fab resulted in lower renal radioactivity levels than those from 64Cu-labeled Fab using a conventional method, without a reduction in the tumor radioactivity levels. These findings indicate that our approach to reducing renal radioactivity levels by liberating a radiolabeled compound from antibody fragments at the renal BBM for urinary excretion is applicable to 64Cu-labeled antibody fragments and useful for immuno-PET and radioimmunotherapy.
Collapse
Affiliation(s)
- Hiroyuki Suzuki
- Laboratory
of Molecular Imaging and Radiotherapy, Graduate School of Pharmaceutical
Sciences, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba, Chiba 260-8675 Japan
| | - Shota Kise
- Laboratory
of Molecular Imaging and Radiotherapy, Graduate School of Pharmaceutical
Sciences, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba, Chiba 260-8675 Japan
| | - Yuta Kaizuka
- Laboratory
of Molecular Imaging and Radiotherapy, Graduate School of Pharmaceutical
Sciences, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba, Chiba 260-8675 Japan
| | - Reo Watanabe
- Laboratory
of Molecular Imaging and Radiotherapy, Graduate School of Pharmaceutical
Sciences, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba, Chiba 260-8675 Japan
| | - Tsubasa Sugawa
- Laboratory
of Molecular Imaging and Radiotherapy, Graduate School of Pharmaceutical
Sciences, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba, Chiba 260-8675 Japan
| | - Takako Furukawa
- Nagoya
University Graduate School of Medicine, 1-1-20 Daiko-Minami, Higashi-ku, Nagoya, Aichi 461-8673, Japan
| | - Hirofumi Fujii
- Division
of Functional Imaging, Exploratory Oncology Research and Clinical
Trial Center, National Cancer Center, 6-5-1 Kashiwanoha, Kashiwa, Chiba 277-8577, Japan
| | - Tomoya Uehara
- Laboratory
of Molecular Imaging and Radiotherapy, Graduate School of Pharmaceutical
Sciences, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba, Chiba 260-8675 Japan
| |
Collapse
|